StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen IMDELLTRA / IMDYLLTRA (tarlatamab-dlle by Year

IMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — U.S. product sales ($M) ($M)

QuarterlyAnnual

Amgen IMDELLTRA / IMDYLLTRA (tarlatamab-dlle: $513M in FY2025, up 346.1% from a year earlier.

Latest, FY2025
513
Period ended Dec 31, 2025
Change on a year earlier
+346.1%
115 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below

Where the FY2025 figure comes from

“|| IMDELLTRA — U.S. | 513 | * | 115 | N/A | —”

Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — U.S. product sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025513+346.1%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
FY2024Dec 31, 2024115–Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗

Cite this data

StockData. (2026). Amgen IMDELLTRA / IMDYLLTRA (tarlatamab-dlle ($M), annual FY2024–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-imdelltra-us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.